CD82 and prostate cancer: However, if CD82 is downregulated below a certain level during malignant progression, fibronectin matrix can activate its receptor integrins so that prostate cancer cells receive strong enough adhesion signals to induce EMT, resulting in the development of a motile mesenchymal phenotype.